Merlin Keep Up to Date with Industry News

Keeping up to date with the latest news within the pharmaceutical industry is important. Merlin strives to remain informed of the latest trends to help support the pharmaceutical industry. By keeping up to date with industry developments regarding the COVID-19 pandemic and responding to requests for new ways of working.

Our team continues to extend their pharmaceutical knowledge to bring access to new ideas to the industry. We have been helping others by providing remote presentations to industry colleagues and clients, to keep them informed on tablet compression theory and pharmaceutical development.

Maintaining Communication

As we approach our tenth year of operation, we have always maintained communications with the pharmaceutical industry to keep ourselves informed, but throughout 2020 and 2021, it has been more important than ever. Pharmaceutical practices have transformed dramatically in the past year, demanding swifter testing procedures, and more flexible approaches, with a higher demand placed on predictive science when conventional routes are temporarily unavailable.

The feedback from our clients shows the positive benefits of early characterisation. Unfortunately, some treatments may develop manufacturing issues during scale-up which will be costly in time and money to solve.

Outsource to Ensure Productivity & Consistency

In-house testing laboratories have now changed their ways of working, by often outsourcing testing to laboratories such as Merlin to ensure productivity and consistent test results are maintained. It is therefore important that we continue to keep up with progress within these companies, and in the industry as a whole.

Webinars have been an important source of information over the last year to ensure we continue to work with the latest information provided. Remaining informed allows us to continue providing quality consultations and advice to our customers on the best powder characterisation tests for their requirements.

Customer demands and risks within the industry are monitored closely, such as the need to achieve the same quality of tests and results previous to the pandemic, but at a faster pace. This is as pharmaceutical development is being scrutinised closer than ever before, and treatments are required swiftly to protect global health.

Smaller sample sizes allow us to maintain testing in a cost-effective and swift process, to generate accurate test results for our customers using the latest industry technology and developments.